Among patients with low-risk pulmonary embolism, 18 months of anticoagulation significantly reduced its recurrence, compared with 6 months of treatment.
Cancer is a well-known risk factor for incident and recurrent venous thromboembolism (VTE), including pulmonary embolism (PE). However, the optimal duration of anticoagulation in patients with cancer and low-risk PE is unknown. In an open-label, multicenter, manufacturer-supported trial in Japan (NCT04724460), investigators randomized 179 patients with cancer-associated acute PE to 6 or 18 months of anticoagulation with rivaroxaban.
According to the simplified Pulmonary Embolism Severity Index, participants were low risk (other than cancer); 88% had incidental PE. Despite the study's premature termination due to slow recruitment, the primary outcome of recurrent VTE at 18 months occurred significantly less frequently with 18 than with 6 mont…
Reviewing Author
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis